Derivatives of 5-pyridinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics
AssigneeSanofi
InventorsFrederic Galli, Odile Leclerc, Alistair Lochead, Julien Vache
Life of this patent
Estimating the term…
Abstract
The invention relates to compounds having general formula (I), wherein R is as defined herein. The invention also relates to acid addition salt, a hydrate or a solvate of compounds of formula (I). The invention further relates to the method of preparing said compounds and to the use of same in therapeutics.
Claims16
A method of treating a disorder associated with dysfunction of the nicotinic receptors, comprising administering to a patient in need of said treatment a therapeutically effective amount of a compound of formula (I):
- in which:
- R represents a group chosen from pyrazolyl, imidazolyl, triazolyl, oxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl and tetrazolyl, said group optionally substituted with one or more groups chosen from halogen, (C1-C6)alkyl, (C1-C6)alkoxy, trifluoromethoxy, trifluoromethyl, nitro, cyano, hydroxyl, amino, (C1-C6)alkylamino and di(C1-C6)alkylamino group;
- and wherein
- the carbon-carbon bond between positions 3 and 4 of the azabicyclooctane ring is a single or a double bond;
- or a pharmaceutically acceptable salt thereof;
- wherein the disorder is selected from the group consisting of executive function disorders associated with Alzheimer's disease and schizophrenia.
A method of inhibiting a nicotinic receptor, comprising administering to a patient in need of said inhibition a therapeutically effective amount of a compound of formula (I):
- in which:
- R represents a group chosen from pyrazolyl, imidazolyl, triazolyl, oxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl and tetrazolyl, said group optionally substituted with one or more groups chosen from halogen, (C1-C6)alkyl, (C1-C6)alkoxy, trifluoromethoxy, trifluoromethyl, nitro, cyano, hydroxyl, amino, (C1-C6)alkylamino and di(C1-C6)alkylamino group;
- and wherein
- the carbon-carbon bond between positions 3 and 4 of the azabicyclooctane ring is a single or a double bond;
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.